3843de1d-0eaa-48af-be58-903fcf2e5f89
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 62.5051334702259
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- HEDGEHOG_SIGNALING+0.360
- MYOGENESIS+0.340
- COAGULATION+0.320
- TNFA_SIGNALING_VIA_NFKB+0.320
- CHOLESTEROL_HOMEOSTASIS+0.310
- APICAL_SURFACE+0.290
- APICAL_JUNCTION+0.280
- ANGIOGENESIS+0.270
- HYPOXIA+0.270
Top 10 suppressed
- E2F_TARGETS-0.460
- INTERFERON_ALPHA_RESPONSE-0.420
- G2M_CHECKPOINT-0.410
- PROTEIN_SECRETION-0.370
- INTERFERON_GAMMA_RESPONSE-0.350
- MYC_TARGETS_V1-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
- SPERMATOGENESIS-0.250
- MTORC1_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R314 | — | — | 0.879 |
| 2 | TCGA-3C-AALK-01A-11R-A41B-07 | — | A | 0.857 |
| 3 | R7 | — | — | 0.846 |
| 4 | GSM6454741 | — | D | 0.846 |
| 5 | SRR975596 | — | — | 0.842 |
| 6 | 69d9a82b-5c37-45bd-a1cf-ffe1392e84fc | — | — | 0.840 |
| 7 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.839 |
| 8 | SRR5088831 | — | — | 0.837 |
| 9 | R86 | — | — | 0.833 |
| 10 | 57583139-d2d3-4b97-a616-aa96058d4682 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |